Return to Listing

2 result(s) for Faslodex

PI Name Protocol # Title
Kathleen Kemmer IRB00009076 A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment
Jacqueline Vuky STUDY00015006 A Phase III, Double-Blind Placebo-Controlled, Randomized Study of Taselisib plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer who have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy.
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080